Table 3.
Baseline characteristics of participants TOTAM trial (n = 145)
| Characteristic | N (%) or median (interquartile range) |
|---|---|
| Age, years | 57.0 (46.0–66.0) |
| BMI, kg·m−2 | 25.9 (22.9–28.7) |
| Tumour stage | |
| T1 | 67 (46) |
| T2 | 67 (46) |
| T3/4 | 11 (8) |
| Nodal stage | |
| N0 | 79 (55) |
| N1 | 49 (34) |
| N2 | 12 (8) |
| N3 | 5 (3) |
| Histologic classification | |
| Ductal adenocarcinoma | 100 (69) |
| Lobular adenocarcinoma | 34 (23) |
| Mucinous carcinoma | 4 (3) |
| Other | 7 (5) |
| Histologic grade | |
| 1 | 20 (14) |
| 2 | 94 (65) |
| 3 | 31 (21) |
| ER status | |
| Positive | 145 (100) |
| PR status | |
| 0% | 16 (11) |
| 1–10% | 14 (10) |
| > 10% | 115 (79) |
| HER2 status | |
| Positive | 13 (9) |
| Surgery | |
| Mastectomy | 63 (43) |
| Lumpectomy | 82 (57) |
| Radiotherapy | |
| Yes | 106 (73) |
| Neo-adjuvant chemotherapy | |
| Yes | 28 (19) |
| Adjuvant chemotherapy | |
| Yes | 32 (22) |
BMI body mass index, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, UM ultra-rapid metabolism, EM extensive metabolism, IM intermediate metabolism, PM poor metabolism, PR progesterone receptor